The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma

• DOI: 10.1038/s41467-018-04006-0
• Publication Date: 2018-04-16T10:07:28Z
• Authors: Zhe Li; Jiwei Zhang; Xinyang Liu; Shengli Li; Qifeng Wang; Di Chen; Zhixiang Hu; Tao Yu; Jie Ding; Jinjun Li; Ming Yao; Jia Fan; Shenglin Huang; Qiang Gao; Yingjun Zhao; Xianghuo He
• Keywords: Intergenic region

Recurrent chromosomal aberrations have led to the discovery of oncogenes or tumour suppressors involved in carcinogenesis. Here we characterized an oncogenic long intergenic non-coding RNA frequent DNA-gain regions hepatocellular carcinoma (HCC), LINC01138 (long located on 1q21.2). The locus is frequently amplified HCC; transcript stabilized by insulin like growth factor-2 mRNA-binding proteins 1/3 (IGF2BP1/IGF2BP3) and associated with malignant features poor outcomes HCC patients. acts as driver that promotes cell proliferation, tumorigenicity, invasion metastasis physically interacting arginine methyltransferase 5 (PRMT5) enhancing its protein stability blocking ubiquitin/proteasome-dependent degradation HCC. LINC01138, a promising prognostic indicator, provides insight into molecular pathogenesis HCC, LINC01138/PRMT5 axis ideal therapeutic target for treatment.